



Please type a plus sign (+) inside this box → []

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3782747_1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	†
		Number	Kind Code (if known)				
CK	AA	6,891,036	B2	Inalco S.p.A.	05-10-2005		

Tamerlani, et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	†
		Office ²	Number	Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
CK	AB	ŽEMLIČKA, J., et al., "Substrate specificity of ribosomal peptidyltransferase. Effect of modification in the heterocyclic, carbohydrate and amino acid moiety of 2'(3')-O-L-phenyladenosine," <i>Biochemistry</i> , 14(24):5239-5249 (02 December 1975).	
CK	AC	ŽEMLIČKA, J., et al., "Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. VIII. The preparation of 2'(3')-O-L-phenylalanyluridine, -cytidine, -adenosine, -inosine, -guanosine and 2'-deoxy-3'-O-L-phenylalanyladenosine," <i>Collection Czechoslov. Chem. Commun.</i> , 43(13):3755-3767 (1969).	

Examiner Signature	G. Krizlman	Date Considered	12/5/06
-----------------------	-------------	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-027-999	10/735,408
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2099
	FILING DATE	ART UNIT
	December 12, 2003	1623

U.S. PATENT DOCUMENTS					
*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes
CE	A121	2004/0067901	4/8/04	Bhat et al.	
	A122	2004/0072788	4/15/04	Bhat et al.	
	A123	2004/0077587	4/22/04	Sommadossi, et al.	
	A124	2004/0097461	5/20/04	Sommadossi, et al.	
	A125	2004/0097462	5/20/04	Sommadossi, et al.	
	A126	2004/0101535	5/27/04	Sommadossi, et al.	
	A127	2004/0102414	5/27/04	Sommadossi, et al.	
	A128	2004/0110717	6/10/04	Carroll, et al.	
	A129	2004/0110718	6/10/04	Devos, et al.	
	A130	2004/0121980	6/24/04	Martin, et al.	
	A131	2005/0124532	6/09/05	Sommadossi, et al.	
	A132	2004/0147464	7/29/04	Roberts, et al.	
	A133	2004/0229839	11/18/04	Babu, et al.	
	A134	2004/0248844	12/9/04	Ismaili, et al.	
	A135	2004/0259934	12/23/04	Olsen, et al.	
	A136	2004/0266722	12/30/04	Devos, et al.	
	A137	2004/0266723	12/30/04	Otto, et al.	
	A138	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	Rabi
	A139	2005/0009737	1/13/05	Clark, et al.	
	A140	2005/0020825	1/27/05	Storer, et al.	
	A141	2005/0031588	2/10/05	Sommadossi, et al.	
	A142	2005/0038240	2/17/05	Connolly, et al.	
	A143	2005/0090463	4/28/05	Roberts, et al.	
	A144	2005/0101530	5/12/05	Roberts, et al.	
	A145	2005/0107312	5/19/05	Keicher, et al.	
	A146	2005/0113330	5/26/05	Imbach, et al.	
	A147	2005/0119200	6/2/05	Roberts, et al.	
	A148	2005/0137141	6/23/05	Hilfinger, et al.	
	A149	2005/0215511	9/29/05	Roberts, et al.	
GL	A150	2006/0040890	3/23/06	Martin; Joseph Armstrong, et al.	

LAI-2912074v1

EXAMINER

G. Kristian

DATE CONSIDERED

12/28/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.